• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    RAPT Therapeutics to Participate in Upcoming Investor Conferences

    6/4/25 4:05:00 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPT alert in real time by email

    SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June:

    • Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on Tuesday, June 10, 2025 at 9:20 a.m. ET

    • UBS Spring Biotech Conference – Investor one-on-one meetings on Tuesday, June 24, 2025

    To access the live webcast or subsequent archived recording of the Goldman Sachs fireside chat, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

    About RAPT Therapeutics, Inc.

    RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.

    RAPT Investor Contact:

    Sylvia Wheeler

    [email protected]

    RAPT Media Contact:

    Aljanae Reynolds

    [email protected]



    Primary Logo

    Get the next $RAPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAPT

    DatePrice TargetRatingAnalyst
    5/22/2025$6.00Buy
    H.C. Wainwright
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    11/13/2024$7.00 → $2.00Buy → Hold
    Stifel
    11/11/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    11/11/2024Neutral → Underweight
    JP Morgan
    5/14/2024Outperform → Peer Perform
    Wolfe Research
    5/10/2024Buy → Neutral
    Guggenheim
    5/10/2024$13.00 → $4.00Overweight → Equal Weight
    Barclays
    More analyst ratings